<--- Back to Details
First PageDocument Content
Combination drugs / Phenols / Phenethylamines / Chronic lower respiratory diseases / Formoterol / Salmeterol / Asthma / Budesonide/formoterol / Fluticasone/salmeterol / Pulmonology / Respiratory therapy / Medicine
Date: 2012-02-06 11:13:40
Combination drugs
Phenols
Phenethylamines
Chronic lower respiratory diseases
Formoterol
Salmeterol
Asthma
Budesonide/formoterol
Fluticasone/salmeterol
Pulmonology
Respiratory therapy
Medicine

Kansas Drug Utilization Review Newsletter Published by Health Information Designs, Inc. Spring 2010 Welcome to the spring 2010 edition of the “Kansas Drug Utilization Review Newsletter,” published by Health Informati

Add to Reading List

Source URL: www.kdheks.gov

Download Document from Source Website

File Size: 199,50 KB

Share Document on Facebook

Similar Documents

EZ-SCREEN® CUP Package Insert-II  The EZ-SCREEN® Cup products are rapid qualitative screening assays for the detection of any combination of the following drugs or their metabolites in human urine: Amphetamine, Barbitu

EZ-SCREEN® CUP Package Insert-II The EZ-SCREEN® Cup products are rapid qualitative screening assays for the detection of any combination of the following drugs or their metabolites in human urine: Amphetamine, Barbitu

DocID: 1vnGd - View Document

SCUDEM 2017 Problem B - Drug Interactions Patients undergoing medical treatment may be given a combination of drug therapies, and the information about the interaction between drugs can be limited[1]. One commonly prescr

SCUDEM 2017 Problem B - Drug Interactions Patients undergoing medical treatment may be given a combination of drug therapies, and the information about the interaction between drugs can be limited[1]. One commonly prescr

DocID: 1uSqq - View Document

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

DocID: 1rqYi - View Document

As at AugustAstraZeneca’s Environmental Risk Summaries As part of AstraZeneca’s ongoing commitment to environmental data transparency, this website provides environmental risk summaries for the Active Pharmace

As at AugustAstraZeneca’s Environmental Risk Summaries As part of AstraZeneca’s ongoing commitment to environmental data transparency, this website provides environmental risk summaries for the Active Pharmace

DocID: 1rlq4 - View Document

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

DocID: 1rhhk - View Document